company background image

Société ADWYABVMT:ADWYA Stock Report

Market Cap







20 Oct, 2021


Company Financials
ADWYA fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

ADWYA Overview

Société ADWYA S.A produces and sells pharmaceutical products in Tunisia.

Price History & Performance

Summary of all time highs, changes and price drops for Société ADWYA
Historical stock prices
Current Share Priceد.ت4.26
52 Week Highد.ت3.89
52 Week Lowد.ت5.28
1 Month Change-9.36%
3 Month Change-16.31%
1 Year Change0.24%
3 Year Change-7.39%
5 Year Change-17.27%
Change since IPO108.43%

Recent News & Updates

Shareholder Returns

ADWYATN PharmaceuticalsTN Market

Return vs Industry: ADWYA underperformed the TN Pharmaceuticals industry which returned 89.6% over the past year.

Return vs Market: ADWYA matched the TN Market which returned 0.3% over the past year.

Price Volatility

Is ADWYA's price volatile compared to industry and market?
ADWYA volatility
ADWYA Beta0.16
Industry Beta0.56
Market Beta1

Stable Share Price: ADWYA is more volatile than 75% of TN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ADWYA's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of TN stocks.

About the Company


Société ADWYA S.A produces and sells pharmaceutical products in Tunisia. The company was founded in 1983 and is headquartered in La Marsa, Tunisia.

Société ADWYA Fundamentals Summary

How do Société ADWYA's earnings and revenue compare to its market cap?
ADWYA fundamental statistics
Market Capد.ت97.95m
Earnings (TTM)-د.ت2.22m
Revenue (TTM)د.ت87.45m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADWYA income statement (TTM)
Cost of Revenueد.ت54.96m
Gross Profitد.ت32.49m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)-0.10
Gross Margin37.15%
Net Profit Margin-2.54%
Debt/Equity Ratio137.7%

How did ADWYA perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Société ADWYA undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ADWYA (TND4.26) is trading below our estimate of fair value (TND24.39)

Significantly Below Fair Value: ADWYA is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: ADWYA is unprofitable, so we can't compare its PE Ratio to the African Pharmaceuticals industry average.

PE vs Market: ADWYA is unprofitable, so we can't compare its PE Ratio to the TN market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADWYA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ADWYA is overvalued based on its PB Ratio (2.6x) compared to the XF Pharmaceuticals industry average (1.6x).

Future Growth

How is Société ADWYA forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Société ADWYA has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Société ADWYA performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ADWYA is currently unprofitable.

Growing Profit Margin: ADWYA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ADWYA is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.

Accelerating Growth: Unable to compare ADWYA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADWYA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).

Return on Equity

High ROE: ADWYA has a negative Return on Equity (-6.36%), as it is currently unprofitable.

Financial Health

How is Société ADWYA's financial position?

Financial Position Analysis

Short Term Liabilities: ADWYA's short term assets (TND84.7M) exceed its short term liabilities (TND81.0M).

Long Term Liabilities: ADWYA's short term assets (TND84.7M) exceed its long term liabilities (TND14.5M).

Debt to Equity History and Analysis

Debt Level: ADWYA's debt to equity ratio (137.7%) is considered high.

Reducing Debt: ADWYA's debt to equity ratio has increased from 35.3% to 137.7% over the past 5 years.

Debt Coverage: ADWYA's debt is well covered by operating cash flow (58.2%).

Interest Coverage: ADWYA's interest payments on its debt are not well covered by EBIT (1x coverage).

Balance Sheet


What is Société ADWYA current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ADWYA's dividend (2.35%) isn’t notable compared to the bottom 25% of dividend payers in the TN market (2.91%).

High Dividend: ADWYA's dividend (2.35%) is low compared to the top 25% of dividend payers in the TN market (6.68%).

Stability and Growth of Payments

Stable Dividend: Too early to tell whether ADWYA's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if ADWYA's dividend payments are increasing as they only just started paying a dividend.

Current Payout to Shareholders

Dividend Coverage: ADWYA is paying a dividend but the company is unprofitable.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Société ADWYA has no CEO, or we have no data on them.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Société ADWYA S.A's employee growth, exchange listings and data sources

Key Information

  • Name: Société ADWYA S.A
  • Ticker: ADWYA
  • Exchange: BVMT
  • Founded: 1983
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: د.ت97.952m
  • Shares outstanding: 21.53m
  • Website:

Number of Employees


  • Société ADWYA S.A
  • Route de la Marsa Km 14
  • BP 658
  • La Marsa
  • 2070
  • Tunisia


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:28
End of Day Share Price2021/10/20 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.